Puma Biotech Q3 net income $20.3M vs $5.8M YoY; raises FY 2024 guidance

PUMA BIOTECHNOLOGY, INC.

2024-Q3 EPS reported $0.22 revenue$171,391,000

Product revenue $56.1M (+8.7% YoY); total revenue $80.5M including $24.4M royalty revenue.
GAAP EPS $0.41 diluted; adjusted non-GAAP EPS $0.45 diluted.
FY 2024 net product revenue guidance raised to $187-190M (from $183-190M); net income raised to $15-17M.
Cash & securities $97M at Sept 30; operating cash flow $11M in Q3.
Phase II alisertib trials in SCLC and breast cancer on track; interim data expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.